Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
The INSULIN Act of 2026 aims to make insulin more affordable for Americans who need it.
The problem
Insulin prices have risen significantly, making this life-saving medication unaffordable for many diabetic patients. Many Americans struggle to pay for necessary insulin treatments.
The proposal
The bill would likely regulate insulin pricing, expand insurance coverage for insulin, or create programs to help patients afford this medication. Specific provisions are pending committee review.
The impact
Diabetic patients and families would be affected by potential cost reductions. Insurance companies, pharmaceutical manufacturers, and government budgets would also be impacted.
Making insulin more affordable helps diabetics access lifesaving medication. Reduced out-of-pocket costs could improve health outcomes and prevent serious complications.
When patients can afford insulin, they avoid expensive emergency room visits and hospitalizations. This saves money for the healthcare system overall.
Affordable insulin access lets patients manage diabetes effectively. Consistent treatment prevents blindness, kidney disease, and amputation.
Price controls might reduce profits pharmaceutical companies earn from insulin sales. Lower profits could mean less investment in developing new and better insulin products.
If the government subsidizes or controls insulin prices, taxpayers bear the cost. This could increase federal spending and add to the national debt.
Healthcare insurers might increase premiums to offset lower insulin profits. This could raise costs for all insurance customers, not just those using insulin.
Price controls could discourage insulin production or distribution. Shortages might result if manufacturers find it unprofitable to make or sell insulin.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.